Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Columbus, GA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Columbus, GA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Macon, GA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Macon, GA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Savannah, GA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
South Bend, IN
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
South Bend, IN
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Overland Park, KA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
New Orleans, LA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Grand Blanc, MI
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Butte, MT
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Butte, MT
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Omaha, NE
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Brooklyn, NY
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Carlisle, OH
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Carlisle, OH
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Tulsa, OK
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Corvallis, OR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Corvallis, OR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Gresham, OR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Gresham, OR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Portland, OR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Hazleton, PA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Hazleton, PA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Dallas, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Duncanville, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Duncanville, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Fort Worth, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Houston, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Layton, UT
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Layton, UT
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Charlottesville, VA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Seattle, WA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position
An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position
Status: Enrolling
Updated:  2/25/2016
Columbia University Medical Center
mi
from
New York City, NY
An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position
An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position
Status: Enrolling
Updated: 2/25/2016
Columbia University Medical Center
mi
from
New York City, NY
Click here to add this to my saved trials
Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
Double-blinded, Single-center, Parallel-arm Comparison Study of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage
Status: Enrolling
Updated:  3/7/2016
Johns Hopkins Dept. of Dermatology
mi
from
Baltimore, MD
Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
Double-blinded, Single-center, Parallel-arm Comparison Study of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage
Status: Enrolling
Updated: 3/7/2016
Johns Hopkins Dept. of Dermatology
mi
from
Baltimore, MD
Click here to add this to my saved trials
Aromatase Inhibitors in the Treatment of Male Infertility
The Role of Aromatase Inhibitors in the Treatment of Infertility in Obese Male
Status: Enrolling
Updated:  3/8/2016
University of Utah
mi
from
Salt Lake City, UT
Aromatase Inhibitors in the Treatment of Male Infertility
The Role of Aromatase Inhibitors in the Treatment of Infertility in Obese Male
Status: Enrolling
Updated: 3/8/2016
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Scottsdale, AZ
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Los Angeles, CA
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Stanford, CA
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Stanford, CA
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Aurora, CO
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Aurora, CO
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Washington,
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Washington,
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Washington,
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Washington,
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Chicago, IL
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Chicago, IL
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Baltimore, MD
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Boston, MA
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Boston, MA
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Boston, MA
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Boston, MA
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Ann Arbor, MI
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
New Brunswick, NJ
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Albany, NY
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Albany, NY
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
New York, NY
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
New York, NY
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
New York, NY
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
New York, NY
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Cleveland, OH
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Pittsburgh, PA
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Charleston, SC
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Charleston, SC
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Houston, TX
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Houston, TX
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Hamilton,
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Hamilton,
Click here to add this to my saved trials
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial
Status: Enrolling
Updated:  4/4/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial
Status: Enrolling
Updated: 4/4/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial
Status: Enrolling
Updated:  4/4/2016
University of California, San Diego
mi
from
San Diego, CA
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial
Status: Enrolling
Updated: 4/4/2016
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Wound Powder for Pressure Ulcers at End-of-life
Novel Wound Powder RGN107 to Reduce Wound Odor, Pain and Exudate at End-of-life
Status: Enrolling
Updated:  4/4/2016
Roper Hospice
mi
from
Charleston, SC
Wound Powder for Pressure Ulcers at End-of-life
Novel Wound Powder RGN107 to Reduce Wound Odor, Pain and Exudate at End-of-life
Status: Enrolling
Updated: 4/4/2016
Roper Hospice
mi
from
Charleston, SC
Click here to add this to my saved trials